Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Nicolatou Galitis, O (Author) Other; Schiodt, M (Author) Other; Mendes, RA (Author) Other; Ripamonti, C (Author) Other; Hope, S (Author) Other; Drudge Coates, L (Author) Other; Niepel, D (Author) Other; Van den Wyngaert, T (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY

Vol. 127

Pages: 117-135

ISSN: 2212-4403

Indexing

ISI Web of Knowledge - 130 Citations

Scopus - 157 Citations

Other information

Authenticus ID: P-00P-V3P

DOI: 10.1016/j.oooo.2018.09.008

Abstract (EN): Skeletal complications caused by osteoporosis or bone metastases are associated with considerable pain, increased mortality, and reduced quality of life. Furthermore, such events place a burden on health care resources. Agents that prevent bone resorption, such as bisphosphonates or denosumab, can reduce the risk of skeletal-related events and are widely used in patients with osteoporosis or bone metastases of cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but potentially serious, adverse event associated with high cumulative doses of bisphosphonates or denosumab. However, MRONJ can be treated, and the likelihood of the development of this condition can be reduced through prophylactic dental care and the maintenance of good oral hygiene. Dentists, as part of a multiprofessional team, have a critical role in preventing MRONJ. This review describes the incidence and pathophysiology of MRONJ and provides guidance for dental practitioners with regard to the screening, prophylactic treatment, diagnosis, and management of patients with this condition.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 19